EFFECT OF LONGER-TERM ADMINISTRATION OF EVOLOCUMAB IN PATIENTS WITH ANGIOGRAPHIC CORONARY ARTERY DISEASE: RESULTS OF THE GLAGOV OPEN LABELLED EXTENSION STUDY

The GLAGOV study demonstrated that addition of evolocumab to existing optimal statin therapy produced intensive lowering of low-density lipoprotein cholesterol (LDL-C) to very low levels and regression of coronary atherosclerosis compared with continuing statin monotherapy. This open label extension